Figures computed from official regulatory filings — .
Ownershipinsiders 0% · institutions 0%
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Pathfinder Cell Therapy, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
7 buys3 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Gruber Joerg | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | First in 12mo | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | First in 12mo | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Breisgau Bio Ventures S.A.track record | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | SEC |
| Gruber Joerg | BuyD (derivative) | n/a (Converted to USD in the nightly refresh) | First in 12mo | SEC |
| Breisgau Bio Ventures S.A.track record | Award | n/a (No price was disclosed in the filing) | SEC |
| Gruber Joerg | Award | n/a (No price was disclosed in the filing) | SEC |
| FRANKLIN RICHARD L | Award | n/a (No price was disclosed in the filing) | SEC |
| Gruber Joerg | Award | n/a (No price was disclosed in the filing) | SEC |
| Gruber Joerg | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| FRANKLIN RICHARD L | Award | n/a (No price was disclosed in the filing) | SEC |
| FRANKLIN RICHARD L | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |